Skip to main content

Table 6 Serum clinical safety markers, part III

From: Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Variable

T1

T2

T3

Time*group

Time*group*gender

Serum protein (g/dL)

 PLA

7.0 ± 0.4

6.8 ± 0.4

7.0 ± 0.4

Time p= 0.011

G*T*Ge p = 0.97

 LD

7.0 ± 0.5

6.8 ± 0.4

7.0 ± 0.4

G*T p= 0.006

 HD

7.2 ± 0.4

7.0 ± 0.5

6.9 ± 0.3

Albumin (g/dL)

 PLA

4.6 ± 0.4

4.4 ± 0.4

4.5 ± 0.4

Time p= 0.023

G*T*Ge p = 0.67

 LD

4.5 ± 0.3

4.5 ± 0.3

4.6 ± 0.3

G*T p = 0.17

 HD

4.5 ± 0.3

4.5 ± 0.3

4.4 ± 0.2

Globulin (g/dL)

 PLA

2.5 ± 0.3

2.4 ± 0.3

2.5 ± 0.2

Time p = 0.15

G*T*Ge p = 0.85

 LD

2.4 ± 0.4

2.3 ± 0.3

2.5 ± 0.3

G*T p = 0.10

 HD

2.6 ± 0.4

2.5 ± 0.4

2.4 ± 0.4

Albumin/Globulin

 PLA

1.9 ± 0.3

1.9 ± 0.3

1.9 ± 0.3

Time p = 0.76

G*T*Ge p = 0.72

 LD

1.9 ± 0.3

1.9 ± 0.3

1.9 ± 0.2

G*T p = 0.66

 HD

1.8 ± 0.4

1.8 ± 0.4

1.8 ± 0.3

Bilirubin (mg/dL)

 PLA

0.7 ± 0.3

0.7 ± 0.4

0.8 ± 0.5

Time p = 0.84

G*T*Ge p = 0.40

 LD

0.7 ± 0.3

0.7 ± 0.3

0.6 ± 0.3

G*T p = 0.44

 HD

0.7 ± 0.3

0.7 ± 0.3

0.6 ± 0.3

ALP (IU/L)

 PLA

58 ± 17

57 ± 15

58 ± 15

Time p = 0.47

G*T*Ge p = 0.36

 LD

53 ± 11

55 ± 12

57 ± 12

G*T p = 0.25

 HD

65 ± 13

60 ± 15

62 ± 13

AST (IU/L)

 PLA

21 ± 6

19 ± 5

20 ± 4

Time p = 0.12

G*T*Ge p = 0.66

 LD

19 ± 5

18 ± 4

20 ± 7

G*T p = 0.81

 HD

20 ± 6

18 ± 6

20 ± 7

ALT (IU/L)

 PLA

17 ± 7

17 ± 6

17 ± 6

Time p = 0.34

G*T*Ge p = 0.45

 LD

17 ± 7

17 ± 8

23 ± 24

G*T p = 0.19

 HD

19 ± 8

17 ± 12

17 ± 6

  1. Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
  2. Symbols: , different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed